Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
AstraZeneca
Mallinckrodt
Baxter
Moodys

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

JUBLIA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Jublia, and what generic alternatives are available?

Jublia is a drug marketed by Bausch and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has forty-seven patent family members in twenty-one countries.

The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.

Drug patent expirations by year for JUBLIA
Drug Prices for JUBLIA

See drug prices for JUBLIA

Generic Entry Opportunity Date for JUBLIA
Generic Entry Date for JUBLIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JUBLIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dong-A ST Co., Ltd.Phase 4
University of Alabama at BirminghamPhase 4

See all JUBLIA clinical trials

Recent Litigation for JUBLIA

Identify potential future generic entrants

District Court Litigation
Case NameDate
VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. MYLAN PHARMACEUTICALS INC.2019-03-08
VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. APOTEX INC.2019-02-15
VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC.2019-02-08

See all JUBLIA litigation

PTAB Litigation
PetitionerDate
Argentum Pharmaceuticals LLC2017-05-12
Acrux DDS Pty Ltd.2016-11-02

See all JUBLIA litigation

Pharmacology for JUBLIA
Synonyms for JUBLIA
(2R, 3R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidyl)-1-(1,2,4-triazolyl)butan-2-ol
(2R,3R)-2-(2,4-Difluorofenil)-3-(4-metilenopiperidin-1-il)-1-(1H-1,2,4-triazin-1-il)butan-2-ol
(2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylene-1-piperidyl)-1-(1,2,4-triazol-1-yl)butan-2-ol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4-triazole-1-yl)butane-2-ol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidino)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
(2r,3r)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
1-Piperidineethanol, alpha-(2,4-difluorophenyl)-beta-methyl-4-methylene-alpha-(1H-1,2,4-triazol-1- ylmethyl)-, (alphaR,betaR)-
164650-44-6
164905-19-5
2856AH
AC1LAJ21
AK315814
AKOS027323571
AS-30126
BCP11665
C18H22F2N4O
CHEBI:82718
CHEMBL2103877
Clenafin (TN)
CS-3500
CTK5J2975
D10021
DB09040
DTXSID40167787
efinaconazol
EFINACONAZOLE
Efinaconazole (JAN/USAN/INN)
Efinaconazole [USAN:INN]
Efinaconazole; KP-103
Efinaconazole(KP-103)
efinaconazolum
EX-A2643
HSDB 8341
HY-15660
J82SB7FXWB
Jublia (TN)
KB-145948
KP-103
KP103
KS-00000SEK
MolPort-039-139-376
NCGC00390702-01
NFEZZTICAUWDHU-RDTXWAMCSA-N
SCHEMBL300738
UNII-J82SB7FXWB
ZINC6251
Paragraph IV (Patent) Challenges for JUBLIA
Tradename Dosage Ingredient NDA Submissiondate
JUBLIA SOLUTION;TOPICAL efinaconazole 203567 2018-06-06

US Patents and Regulatory Information for JUBLIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bausch JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Bausch JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bausch JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Mallinckrodt
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.